Clinical trials: Inflammatory Bowel Diseases
Ulcerative Colitis
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers
This is a Phase 1, first in human, three-part randomized, double-blind, placebo-controlled dose escalation trial to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of EQ504 following single…
- Trial name
- NCT07869225
- Testing
- EQ504
- Where
- Australia
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Equillium
Ulcerative Colitis
A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)
This study was conducted to determine the efficacy and safety of GWP42003 compared with placebo by the percentage of participants achieving remission quantified as a Mayo score of 2 or less (with no sub-score >1) after 10 weeks…
- Trial name
- NCT01562314
- Testing
- GWP42003
- Where
- 8 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- GW Research Ltd
Inflammatory Bowel Disease, Anemia
FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR
The purpose of this study is to determine how safe, tolerable and effective the new standardised dosage regimen of FERINJECT® infusions is, compared with a well established intravenous iron treatment.
- Conditions
- Inflammatory Bowel Disease, Anemia, Iron Deficiency, Iron-Deficiency Anemia
- Trial name
- FER-IBD-COR (NCT00810030)
- Testing
- Ferric carboxymaltose, Iron Sucrose
- Where
- Austria
- Volunteers
- 484 people
- Sponsor
- Vifor Pharma
Ulcerative Colitis
Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
The purpose of this study is to evaluate efficacy, safety and pharmacokinetics of the vedolizumab (MLN0002) induction and maintenance therapy in Japanese participants with moderate or severe ulcerative colitis (UC).
- Trial name
- NCT02039505
- Testing
- Vedolizumab
- Where
- 59 sites in Japan
- Volunteers
- 292 people
- Sponsor
- Takeda
Inflammatory Bowel Diseases
MACCS: Multicenter Australian CE in Patients With Suspected Crohn's Disease Study
This is a prospective study aimed to validate the ability of capsule endoscopy to accurately diagnose small bowel Crohn's disease in symptomatic patients who have a non-diagnostic standard workup.
- Trial name
- MACCS (NCT00434551)
- Where
- 8 sites in Australia
- Volunteers
- 119 people
- Sponsor
- Medtronic - MITG
Crohn's Disease
Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease
This study is designed to explore mechanism of action of mongersen (GED-0301) 160 mg once daily in patients with active Crohn's Disease
- Trial name
- NCT02685683
- Testing
- GED-0301
- Where
- 2 sites in Italy
- Volunteers
- 18 people
- Sponsor
- Celgene
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Ulcerative Colitis
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.
- Trial name
- NCT00279422
- Testing
- visilizumab
- Where
- 70 sites in United States, Australia and 12 more
- Volunteers
- 127 people
- Sponsor
- Facet Biotech
Iron Deficiency Anemia Secondary to IBD or Gastric Bypass
Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass
The primary objective of this study is to evaluate the treatment response of Injectafer vs. oral iron to baseline hepcidin levels to determine if any of these select IBD or Gastric Bypass patients may demonstrate to be…
- Trial name
- NCT02086968
- Testing
- Injectafer, Ferrous Sulfate tablets
- Volunteers
- 198 people
- Sponsor
- American Regent, Inc.
Inflammatory Bowel Diseases
A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects
This study is the first administration of GSK2982772 in humans. The study will evaluate the safety, tolerability, pharmacokinetics (PK), and exploratory pharmacodynamics (PD) of single and repeat oral doses of up to 14 days with…
- Trial name
- NCT02302404
- Testing
- GSK2982772 solution, GSK2982772 capsule
- Where
- United Kingdom
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Crohn's Disease
Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy
The purpose of this study is to evaluate CROWN's efficacy in supporting the repair and maintenance of the intestinal mucosa of patients with moderately to severely active Crohn's Disease receiving anti-Tumor Necrosis Factor (TNF)…
- Trial name
- PIONEER-CD (NCT02793778)
- Testing
- CROWN
- Where
- 39 sites in United States
- Volunteers
- 42 people
- Sponsor
- Prometheus Laboratories
Crohn's Disease
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
This is a multicenter, randomized, double-blind, placebo-controlled, maintenance, Phase 3 study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease (CD).
- Trial name
- STARSCAPE-2 (NCT07184944)
- Testing
- Duvakitug
- Where
- 109 sites in United States, Australia and 25 more
- Volunteers
- 751 people
- Sponsor
- Sanofi
Ulcerative Colitis
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
This two-part, part 1: open-label extension (OLE) and part 2: safety monitoring (SM) study will examine the efficacy and safety of continued etrolizumab treatment in moderate to severe ulcerative colitis (UC) participants…
- Trial name
- COTTONWOOD (NCT02118584)
- Testing
- Etrolizumab
- Where
- 411 sites in United States, Argentina and 40 more
- Volunteers
- 1,822 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis
Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis
This study was designed to evaluate if subjects who achieve complete remission after 8 weeks of acute therapy with MMX mesalamine/mesalazine 4.8g/day given QD have better long-term outcomes and remain in remission longer compared…
- Trial name
- NCT01124149
- Testing
- MMX mesalamine/ mesalazine
- Where
- 105 sites in United States, Belgium and 13 more
- Volunteers
- 759 people
- Sponsor
- Shire
Crohn's Disease
Safety Study of Entocort for Children With Crohn's Disease
A Safety Study using Entocort EC for children with mild to moderate Crohn's Disease
- Trial name
- NCT01444092
- Testing
- Entocort
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 123 people
- Sponsor
- Padagis LLC
Crohn's Disease
Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008
The purpose of the study is to determine whether an investigational compound, ALX-0600, is safe and effective in treating Crohn's Disease.
- Trial name
- NCT00308438
- Testing
- Teduglutide (ALX-0600)
- Where
- 24 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Shire
Crohn's Disease
Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease
The purpose of this study is to determine the safety, tolerability, and efficacy of natalizumab in individuals diagnosed with active Crohn's Disease that are not in remission (CDAI greater than/equal to 150) and are currently…
- Trial name
- NCT00055536
- Testing
- natalizumab
- Where
- 18 sites in United States
- Volunteers
- 60 people
- Sponsor
- Biogen
Iron Deficiency, Inflammatory Bowel Disease
Maintenance Treatment of Iron Deficiency in IBD Patients
The aim of this study is to evaluate the treatment of iron deficiency in IBD patients.
- Trial name
- FER-IBD-MAIN (NCT00810004)
- Testing
- Ferinject
- Where
- Russia
- Volunteers
- 245 people
- Sponsor
- Vifor Pharma
Colitis, Ulcerative, Crohn Disease
A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants
The purpose of this study is to assess the PK of vedolizumab following a single intravenous infusion in healthy adult Chinese participants.
- Trial name
- NCT03329209
- Testing
- Vedolizumab
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Takeda
Crohn's Disease
A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease
The primary purpose of this multi-centre, double blind-study is to evaluate the clinical response of patients with moderate to severe Cohn's Disease (CD) following treatment with different doses and dose regimens of Olokizumab…
- Trial name
- NCT01635621
- Testing
- Olokizumab (OKZ)
- Sponsor
- UCB BIOSCIENCES GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.